Alluri Amruth A, Salahuddin Namita, Mujoo Tishya, Neelam Soukhya, Thirugnanasambandam Nitish, Shah Priyank
Internal Medicine, American University of the Caribbean School of Medicine, Cupecoy, SXM.
Internal Medicine, Essen Health Care, New York, USA.
Cureus. 2025 Jun 18;17(6):e86274. doi: 10.7759/cureus.86274. eCollection 2025 Jun.
Hyperthyroidism is one of the most frequently diagnosed disorders in the United States (US), and its association with heart failure (HF) remains underexplored. Understanding this relationship is critical for identifying high-risk populations and guiding preventive efforts.
This study aimed to analyze temporal and demographic trends in mortality where hyperthyroidism was the underlying cause and HF a contributing cause, using national data from 1999 to 2020.
A retrospective observational study was conducted using the Centers for Disease Control and Prevention (CDC) Multiple Causes of Death (MCD) database to assess mortality trends in individuals aged ≥25 years in the US from 1999 to 2020. The study included deaths in which hyperthyroidism (ICD-E05) was listed as an underlying cause and HF (ICD-i50) as a contributing cause. Data were analyzed by gender, race, geographic area, and place of death. Age-adjusted mortality rates (AAMRs) and annual percentage changes (APCs) were calculated.
A total of 1,189 deaths were documented. The AAMR initially increased (25.95% APC from 1999 to 2001), followed by a decline from 2001 to 2011 (-5.04% APC); however, it increased from 2011 to 2020 (1.83% APC). The highest mortality was observed in females (70%), White individuals (73.93%), and those living in metropolitan regions (75.4%). Temporal trends showed an increasing AAMR in females (APC: +3.74% after 2013) and White individuals (APC: 8.16% from 2017 to 2020), indicating evolving disparities.
Mortality trends in hyperthyroidism with HF have shifted, with increasing disparities in gender and race. These findings emphasize the need for targeted prevention strategies and improved healthcare access.
甲状腺功能亢进症是美国最常被诊断出的疾病之一，其与心力衰竭（HF）之间的关联仍未得到充分研究。了解这种关系对于识别高危人群和指导预防工作至关重要。
本研究旨在利用1999年至2020年的国家数据，分析以甲状腺功能亢进症为根本原因且心力衰竭为促成原因的死亡率的时间和人口趋势。
采用回顾性观察研究，使用疾病控制与预防中心（CDC）的多重死因（MCD）数据库评估1999年至2020年美国25岁及以上人群的死亡率趋势。该研究包括将甲状腺功能亢进症（国际疾病分类代码-E05）列为根本原因且心力衰竭（国际疾病分类代码-i50）列为促成原因的死亡病例。数据按性别、种族、地理区域和死亡地点进行分析。计算年龄调整死亡率（AAMR）和年度百分比变化（APC）。
共记录了1189例死亡病例。AAMR最初上升（1999年至2001年APC为25.95%），随后从2001年至2011年下降（APC为-5.04%）；然而，从2011年至2020年又有所上升（APC为1.83%）。女性（70%）、白人（73.93%）以及居住在大都市地区的人（75.4%）的死亡率最高。时间趋势显示女性（2013年后APC：+3.74%）和白人（2017年至2020年APC：8.16%）的AAMR上升，表明差距在不断扩大。
甲状腺功能亢进症合并心力衰竭患者的死亡率趋势发生了变化，性别和种族差异不断增大。这些发现强调了制定有针对性的预防策略和改善医疗服务可及性的必要性。
